Rybrevant Faspro is an under-the-skin (subcutaneous, or SC) injection form of the anticancer medicine Rybrevant (amivantamab). The FDA has approved a new monthly dosing option for Rybrevant Faspro to be used in combination with the oral… Read more
Cablivi (caplacizumab) is an injectable medicine used to treat a rare and serious blood condition called acquired thrombotic thrombocytopenic purpura (aTTP). The FDA has approved Cablivi to be used along with plasma exchange and immunosuppressive… Read more
Zycubo (copper histidinate) is a new under-the-skin injection that the FDA has approved for treating children with a rare genetic condition that affects copper metabolism, known as Menkes disease. Menkes disease is caused by mutations… Read more
Accrufer (ferric maltol) is an oral capsule approved by the FDA to treat iron deficiency in kids ages 10 years and older. It helps your body absorb iron through your digestive system, which is important… Read more
Lunsumio Velo (mosunetuzumab-axgb) is a new under-the-skin (subcutaneous) injection version of the anticancer medicine Lunsumio intravenous infusion. The FDA has granted accelerated approval to Lunsumio Velo for treating adults with follicular lymphoma that has come back (relapsed)… Read more
Wegovy (semaglutide) is a prescription medicine that helps with weight loss and lowers the risk of heart problems and liver disease. The FDA has approved its oral pill form to be used alongside a low-calorie… Read more
Jascayd (nerandomilast) is now approved for treating adults with progressive pulmonary fibrosis (PPF) that causes gradual and permanent scarring in the lungs, making it harder to breathe over time. Jascayd was previously approved to treat… Read more
Fesilty (fibrinogen, human-chmt) is a newly approved treatment for sudden bleeding episodes in both children and adults with a rare condition called congenital fibrinogen deficiency (CFD). CFD is a condition where the body makes too… Read more
Rybrevant Faspro is a new under-the-skin (subcutaneous) injection form of the cancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called lazertinib (Lazcluze) as a first-line treatment for a type… Read more
Myqorzo (aficamten) is a new oral medicine approved by the FDA for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). It relieves symptoms, improves heart function, and provides better stamina for daily activities. Hypertrophic cardiomyopathy (HCM)… Read more